Lead Product(s): Diamyd
Therapeutic Area: Endocrinology
Highest Development Status: Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Protein Sciences Corporation
Deal Size: $5.0 million Upfront Cash: $5.0 million
Deal Type: Agreement February 05, 2020
The agreement facilitates the transition of the manufacturing process of recombinant GAD65, to a new manufacturer for future anticipated commercial manufacture.